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Background: Analysis of the International Association for the Study 
of Lung Cancer database revealed that for patients with completely 
resected, node-negative, non–small-cell lung cancer (NSCLC), 
increasing tumor size was associated with worsening survival. This 
analysis was performed to determine the effect of size on prognosis 
in patients in the same database but who were treated with radio-
therapy or chemoradiotherapy.
Methods: Patients were eligible if they had pathologically confirmed 
NSCLC, no evidence of distant metastases, intended treatment was 
radical radiotherapy (minimum 50 Gy) or combined chemotherapy 
and radiotherapy, no surgery, and tumor diameter was available.
Results: Eight hundred and sixty-eight patients were available for 
analysis. Patient characteristics were: sex (men) 65.3%; median 
age 64 years (range, 32–88); Eastern Cooperative Oncology Group 
performance status 0: 55%, 1: 33%, 2 or more: 5%; che motherapy 
74%; no chemotherapy 18%; weight loss less than 5 %: 70%, and 
more than 5%: 25%. Primary tumor size was categorized according 
to tumor, node, metastasis 7th edition. On univariate analysis, the 
following factors were prognostic for survival: age (continuous) (p = 
0.0035); performance status of 1 or more (p = 0.0021); weight loss 
less than 5% (p < 0.0001); chemotherapy (p = 0.0189); and primary 
tumor size (continuous) (p = 0.0002). Sex and clinical nodal stage 
were not significant. On multivariate analysis, age and weight loss 
remained significant factors for survival, as was tumor size less than 
3 cm.
Conclusions: In patients treated with radiotherapy with or without 
chemotherapy, tumor size less than 3 cm was associated with longer 
survival than larger tumors. Evidence of the effect of size on prog-
nosis above this was weak. Five-year survival of more than 10% was 
observed in all four size categories.
Key Words: Non–small-cell lung cancer, Radiotherapy, Prognosis, 
Tumor, node, metastasis stage, Tumor size.
(J Thorac Oncol. 2013;8: 315-321)
The 7th edition of the tumor, node, metastasis (TNM) stag-ing system for lung cancer has five T categories for size: 
T1a, which is 2 cm or less; T1b, greater than 2 cm and up 
to and including 3 cm; T2a, greater than 3 cm and up to and 
including 5 cm; T2b, greater than 5 cm and up to and includ-
ing 7 cm; and T3, tumors greater than 7 cm. These T catego-
ries are derived from an analysis of the staging database of 
the International Association for the Study of Lung Cancer 
(IASLC), which showed worsening prognosis for increasing 
tumor size.1 That analysis was restricted to 8099 patients who 
had complete surgical resection of their disease, and who were 
node-negative, to avoid confounding the effect of size with the 
effect of lymph node involvement.
However, further analyses on 9007 patients who had 
undergone any type of resection (complete and incomplete) 
but whose tumors had no nodal involvement, and on 1,3742 
patients with complete and incomplete resections and with 
tumors including any type of nodal involvement, showed that 
the tumor-size groups were consistent in all these populations.1 
In theory, size should also be important in patients who are 
treated for cure with radiotherapy or chemoradiotherapy. Size 
may be even more directly relevant for local control (without 
which cure cannot be achieved), because the surgeon who 
achieves an R0 resection is able to eradicate all clonogenic 
cells, regardless of the primary tumor size. However, in the 
case of radiotherapy, cell killing is proportional to dose, and 
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therefore, local control is dependent on both the number of 
clonogenic cells and the dose that can be safely administered. 
Indeed, a number of retrospective studies have suggested 
that tumor size is an important prognostic factor in lung 
cancer patients treated by nonsurgical means, particularly 
radiotherapy.2–6 This is consistent with the hypothesis that 
larger tumors are likely to contain more clonogenic cells, and 
it fits with clinical observations of tumor size and local control 
using radiotherapy in other cancer sites.7
We therefore, undertook this study to see whether the T 
stage size categories derived from the surgical population for 
the 7th edition had a similar prognostic effect in patients from 
the same database but who were treated with radiotherapy 
with or without chemotherapy.
PATIENTS AND METHODS
The IASLC Staging Project was established in 1998 to 
inform the 7th edition of the TNM classification. A description 
of the project and the resulting database has been published 
previously.8 More than 100,000 cases were accrued to the data-
base and included patients treated by surgery, radiotherapy and 
chemotherapy, or combinations of these. To be eligible for the 
current analysis, patients on the database had to have a histolog-
ically confirmed diagnosis of NSCLC, no evidence of distant 
metastases, an intended treatment of radical radiotherapy (mini-
mum 50 Gy) or combined chemotherapy and radiotherapy, no 
surgery, and an available tumor diameter . Other prognostic fac-
tor data including patient age, sex, performance status (ECOG), 
and weight loss were also drawn from the database. Unlike the 
initial analysis of the surgical patients, which was restricted to 
pathologically staged N0 cases, this analysis included patients 
with and without clinical lymph node involvement. Because the 
database was restricted to the era before fludeoxyglucose posi-
tron emission tomography became widely available, clinical 
diagnosis of lymph node involvement was unreliable. Further, 
the patients referred for radiotherapy were much more likely to 
have had lymph node involvement than surgical patients, and it 
would have been impractical to perform an analysis restricted 
to radiotherapy patients with negative nodes. However, it was 
intended that an adjustment for any effect of lymph node 
involvement would be undertaken through multivariate analy-
sis, as it would be for other potential prognostic factors.
Statistical Analysis
The Kaplan–Meier estimator was used for survival 
curves. Survival was measured from the start of radiotherapy. 
Survival distributions were compared using the log-rank test. 
Univariate and multivariate Cox regression was used to model 
the effect of primary tumor size and other prognostic factors 
on survival. Stepwise variable selection was used to determine 
significant prognostic factors for the final multivariate model.
RESULTS
There were 868 patients from five separate sources 
available for analysis (Table 1). Patient characteristics are 
listed in Table 2. Survival of patients grouped according to 
size (T1, T2a, T2b, and T3) is shown in Figure 1. Patients with 
TABLE 1.  Patient Data Sources
Data Source n %
M.D. Anderson Cancer Center 241 27.8
National Cancer Institute of Canada 14 1.6
Peter MacCallum Cancer Center 130 15.0
Queensland Radium Institute 21 2.4
Radiotherapy Oncology Group (RTOG) 462 53.2
Total 868 100.0
TABLE 2.  Patient Characteristics
Factor Level n %
Tumor size, cm PT size ≤ 3 233 26.8
PT size > 3 and ≤ 5 297 34.2
PT size > 5 and ≤ 7 175 20.2
PT size > 7 163 18.8
Age, yrs < 56 213 24.5
< 64 223 25.6
< 70 204 23.5
≥ 70 221 25.5
No data 7 0.8
Sex Women 301 34.6
Men 567 65.3
Performance status 0 478 55.1
1 287 33.1
2 44 5.1
No data 59 6.8
Weight loss < 5% 609 70.2
≥ 5% 214 24.7
No data 45 5.2
Chemotherapy Chemotherapy 638 73.5
No chemotherapy 153 17.6
No data 77 8.9
Clinical T T1a 69 8.0
T1b 65 7.5
T2a 271 31.2
T2b 60 6.9
T3 205 23.6
T4 198 22.8
Clinical N N0 158 18.2
N1 43 5.0
N2 545 62.8
N3 122 14.1
7th editionTNM stage IA 37 4.3
IB 38 4.4
IIA 19 2.0
IIB 33 3.8
IIIA 514 59.2
IIIB 227 26.2
PT, primary tumor; TNM, tumor, node, metastasis; PS, performance status.
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tumors less than or equal to 3 cm had significantly longer sur-
vival than patients with tumors larger than 3 cm but smaller 
than or equal to 7 cm. Patients with the largest tumors, that 
is, larger than 7 cm, had the worst survival, but this did not 
achieve statistical significance compared with T2b tumors (p 
= 0.11). Five-year survival above 10% was observed in all the 
four size categories. The influence of other prognostic factors 
is shown in Table 3. On univariate analysis, age, performance 
status, weight loss, chemotherapy, T category, and tumor 
size were all significant prognostic factors, but sex and clini-
cal node status were not (Table 4). On multivariate analysis, 
age, weight loss, and tumor size equal to or less than 3 cm 
remained significant prognostic factors, but there was little 
evidence that size beyond this was prognostic (Table 5).
DISCUSSION
This analysis of the IASLC staging database is the first 
to study the relationship between survival and the tumor-size 
groupings of the TNM 7th edition in patients with NSCLC 
treated with radiotherapy instead of surgery. It reveals that 
patients with T1 tumors (7th edition) have longer survival than 
patients with T2 and T3 tumors categorized according to size, 
but it failed to provide evidence that there was a prognostic 
effect of size within the T2a and T2b categories. The survival 
of T3 tumor patients was shorter than for T2 tumor patients, 
but this did not achieve statistical significance. Five-year sur-
vival from the beginning of radiotherapy was similar for all 
four size groups, within the range of 10% to17% and all with 
overlapping 95% confidence intervals.
Several reasons can be advanced for the failure of this 
study to detect a convincing prognostic effect of tumor size 
beyond the T1 category. First, the population studied was 
different because unlike the surgical population, cases with 
involved nodes were eligible, and the effect of node involve-
ment may have partly masked the effect of primary tumor size. 
That is, the worse prognosis conferred by node involvement 
and associated risk of distant metastasis overrode any adverse 
influence of increasing tumor size on local control as a com-
peting risk for death. However, clinical N status overall was 
not in itself prognostic in this study, so this is unlikely to be the 
explanation for the absence of a prognostic effect of increas-
ing tumor size beyond T1. In a previous publication based on 
the IASLC database, clinical N status was strongly prognostic, 
but this was driven mostly by the outcomes in patients who 
underwent surgical treatment.9 The authors were unable to 
determine why clinical nodal status had little prognostic effect 
in nonsurgical patients, but suggested less effective treatment 
or the presence of comorbidities as possible explanations.
Second, it is possible that the prognostic effect of 
size varies according to the treatment given, that is, it is 
predictive rather than prognostic. As mentioned earlier, the 
size of the primary tumor may have different implications 
based on whether the cancer was removed surgically, or 
treated with (chemo)radiation. In the case of the surgically 
treated patient, increasing size (and with it the number of 
clonogenic cells) may be associated with increasing risk of 
distant metastasis, but may have little influence on technical 
resectability and local control. However, tumor size may be a 
major determinant of local control in the radiotherapy patient, 
if size is a surrogate for the number of clonogenic cells, and 
there is a limit to the dose of radiotherapy that can be given. 
It has been estimated that a 1-cm tumor contains 109 cells, 
a 3-cm tumor somewhere between 1010 and 1011 cells, and a 
5-cm tumor a little over 1011 cells.10 A 7-cm tumor contains 
approximately 1011.5 cells. Because cell killing by radiation is 
exponential, there should be a size–response effect for a fixed 
dose of radiation over the range of sizes represented by the T 
categories (assuming all the cells are clonogenic). The size 
of the effect should progressively diminish with increasing T 
size. The tumor may also be made up of stroma, inflammatory 
cells, and necrotic material as well as clonogenic cells, and 
intertumor variation in the proportions of these components 
may account for differences in response between tumors of 
similar size. Tumors also vary in their radiosensitivity, either 
an intrinsic genetically determined characteristic, or as a 
result of the presence or absence of tumor hypoxia. These 
factors, alone or in combination, may affect the probability of 
local control independently of the tumor size in an irradiated 
tumor, but not in one that has been resected. Finally, in this 
analysis no adjustment has been made for the prognostic 
effect of comorbidities, which are likely to be more important 
in a radiotherapy population compared with patients who are 
fit enough to undergo surgical resection.
A number of retrospective studies have analyzed the 
relationship between tumor size and survival in patients 
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FIGURE 1.  Survival according to PT size (cm). PT, 
primary tumor.
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with nonmetastatic NSCLC treated with radiotherapy, with 
and without chemotherapy.2–6,11,12 The largest study had 270 
patients. All these studies demonstrated worse survival associ-
ated with increasing tumor size, but methodologic differences 
limit comparison with the present report. In none of the stud-
ies were the data analyzed according to the size groupings of 
the TNM 7th edition. Tumor size was sometimes treated as 
a continuous variable and sometimes as a dichotomous vari-
able divided by the median value. In three studies, tumor size 
was calculated by adding the sizes of the primary tumor and 
the lymph nodes together.4,5,11 Seven studies allowed the use 
of induction chemotherapy, and it is not always clear whether 
size was measured before chemotherapy, or after chemother-
apy but before radiotherapy.2–6,11,12 In the present study tumor 
size was measured before any treatment was given.
One prospective study of 509 patients treated with 
radiotherapy, with or without chemotherapy, assessed the 
effect of tumor volume on survival.13 Size was analyzed both 
as a continuous variable and grouped by quartiles, and before 
any treatment was given. There were some similarities in 
the findings in that study and the present report. The small-
est tumors in the lowest quartile had the best prognosis, but 
beyond that, the impact of size was less evident, as seen in 
the IASLC patients. Tumor size also had little effect on 5-year 
TABLE 3.  Survival According to Primary Tumor Size and Other Prognostic Factors
Factor Level Median Survival
Median 95% CI
5-Year Survival Estimate (%)
5-Yr. Survival 95% CI
Lower Upper Lower (%) Upper(%)
Tumor size, cm PT size ≤ 3 1.8 1.5 2.1 16.9 12.1 22.4
PT size > 3 and ≤ 5 1.3 1.2 1.5 12.9 9.2 17.3
PT size > 5 and ≤ 7 1.4 1.2 1.6 16.3 11.0 22.5
PT size > 7 1.1 0.9 1.3 10.2 5.8 15.9
Age, yrs < 56 1.4 1.3 1.7 17.2 12.1 23.1
< 64 1.5 1.3 1.7 14.0 9.6 19.2
< 70 1.5 1.3 1.8 14.2 9.4 19.9
≥ 70 1.2 0.9 1.3 10.7 6.8 15.5
No data 0.7 0.4 1.9 28.6 4.1 61.2
Sex Women 1.6 1.3 1.7 16.2 11.9 21.0
Men 1.3 1.2 1.4 13.1 10.3 16.3
Performance status 0 1.4 1.3 1.7 17.3 13.9 21.0
1 1.3 1.2 1.4 10.0 6.6 14.2
≥2 1.2 0.9 1.6 9.6 3.1 20.6
No data 1.6 1.1 2.1 4.6 0.4 18.5
Weight loss < 5% 1.6 1.4 1.7 16.6 13.5 19.9
≥ 5% 1.0 0.8 1.2 8.7 5.3 13.1
No data 1.2 0.9 1.6 7.8 2.1 18.4
Chemotherapy Chemotherapy 1.4 1.3 1.6 16.3 13.3 19.6
No chemotherapy 1.2 1.0 1.4 10.3 6.1 15.7
No data 1.4 1.1 1.8 5.8 1.9 12.8
Clinical T T1a 1.6 1.3 2.1 15.5 7.7 25.7
T1b 2.6 2.1 3.2 22.6 13.0 33.8
T2a 1.3 1.2 1.5 12.1 8.2 16.7
T2b 1.3 0.9 1.9 16.9 8.4 28.0
T3 1.3 1.1 1.4 13.3 8.9 18.6
T4 1.3 1.2 1.4 14.0 9.2 19.9
Clinical N N0 1.6 1.3 1.8 12.2 7.6 18.0
N1 1.4 1.1 2.1 8.4 2.2 20.0
N2 1.4 1.2 1.5 15.7 12.5 19.2
N3 1.3 1.0 1.4 12.8 7.4 19.9
7th edition
TNM stage
IA 2.0 1.5 2.9 16.2 6.6 29.6
IB 1.3 0.8 1.8 2.6 0.2 11.8
IIA 2.3 0.9 3.2 15.8 3.9 34.9
IIB 1.7 1.3 2.0 15.2 5.5 29.2
IIIA 1.4 1.2 1.6 15.6 12.4 19.2
IIIB 1.3 1.2 1.4 13.0 8.7 18.1
PT, primary tumor; CI, confidence interval; TNM stage, tumor, node, metastasis stage; PS, performance status.
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survival in both studies. The clinical implication of this last 
observation is that tumor size alone should not influence the 
decision to give radiotherapy with curative intent.
In summary, the effect of increasing tumor size on prog-
nosis was less evident in patients treated with (chemo)radio-
therapy (except for T1 patients) than for patients treated with 
surgery, or in most of the existing radiotherapy literature. This 
finding has been independently supported by the results of a 
prospective and methodologically rigorous cooperative group 
trial,13 indicating that it is unlikely to be a chance finding. 
Therefore, this study alerts us to the possibility that the tumor 
size descriptors may not have the same applicability to patients 
treated by (chemo)radiotherapy as they do for patients treated 
surgically, at least, in terms of prognosis. Future editions of 
TNM will be informed by a prospective database that is actively 
accruing at the time of writing.14 We hope the cases added to 
the database will provide sufficient numbers of patients in all 
treatment groups so that a broadly relevant staging system can 
be developed and used, regardless of which treatment is applied.
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